Board of Directors
Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.
In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.
Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and serves as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.
Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.
Ronen Twito CPA
Chairman of the Board
Mr. Twito brings with him over 20 year of financial and managerial experience, executive positions and an investor in NASDAQ and TASE listed companies. Mr. Twito is the founder of Amplify Capital Ltd. He led multiple IPOs, and follow on offerings, strategic licensing and collaboration agreements mainly within the biotech and technology spaces such as XTL Biopharmaceuticals “XTLB“, Cellect Biotechnology “APOP”, BioBlast pharma “ORPN”, “MTSL”. Prior to that, served at a global Telecom company listed on London LSE and as a senior manager at EY. Ronen is a Certified Public Accountant (CPA), Israel, He has a B.A. in Business and Management: Major - Accounting from Management College (The
Michlala L’Minhal Collman) Ronen is a member of the Institute of CPAs in Israel.
Mr. Olivier Samuel has been running consulting activity since 2001, in operational and strategic project management specialized in the field of health, in particular in the fields of geriatric care and healthcare management on behalf of leading operators and brands in the field of medical equipment, retirement homes, telecommunication operators, health insurance and investment funds.
He has been a member of the board of Kadimastem since 2010 on behalf of Mr Julien Ruggierie. Since 2020 Olivier has been serving as a board member of Kadimastem.
Mr. Samuel is a graduate of EM Lyon and the Lille School of Health Engineers.
Mr. Samuel was the CEO from 1997 to 2020 was the CEO of Adomsante in France, a company specialized in home care and medical equipment for the elderly in France.
Ron Mayron is the founder and CEO at RonMed Ltd. There he leads a company that consultants to healthcare companies, their core expertise are mergers & acquisitions, integration and implementation, global business development, global operations & supply chain. Ron brings with him extensive, long-term experience in the local & global pharmaceutical and medical device arena. Before that Ron worked at Teva Pharmaceutical industries Ltd. for 21 years leaving as Vice President Israel & Africa & CEO Teva Israel. Ron is now serving as an active director for 9 different companies and has served at 6 others mainly in the healthcare, medical device, pharmaceutical and biotech fields. Ron has a M.B. A, from the University of Tel-Aviv; majored in information systems with secondary stream in Technology Management and Operational Systems, and a B.Sc. from the Industrial & Management Engineering, Ben-Gurion University of the Negev; majored in Information Systems.
Since 2009 Doron has been the CEO of Doron Birger Management and Consulting. He is the active chairman of a number of technology companies: Sight Diagnostic, Onsight, Nurami and Matricelf. From 2002-2007 Doron was the Chairman and Director in Given Imagine (Nasdaq/TASE-GIVN ) and director at Icecure (TASE:ICECURE), Heramed (ASX:HMD ), Citrine Global Corp. (OTCQB:CTGL), Vibrant and Netive Haor. Doron was a special consultant at Vimodo; a company that invests in the field of cancer research and treatment. Doron was also the CEO and Special consultant of Landmark Ventures Israel; a US hi- tech investment banking firm. From 2002-2009 Doron was the President and Chief Executive Officer of Elron Electronic Industries Ltd. There he advanced Elron as a leading high-tech group in Israel including 27 companies, 3 of them publicly traded, focused in the fields of Medical Devices, as well as communications, Software, Clean Tech and Semiconductors.
Tammy Galili is the CEO of Ilex Medical Ltd., since 2016. Ilex Medical Ltd. is a leading company in the medical diagnostics industry. Ms. Galili has more than three decades of experience in various positions at Ilex Medical, including VP of Operations, HR Manager and Quality Control Manager. Her more recent positions were Deputy CEO from 2014 to 2016 and VP of Sales & Marketing in 2010. Ms. Galili is one of 4 female CEO’s in the TA-125 index, also chosen as one of the Top Best CEO’s in Israel in 2020 by Calcalist Magazine. She has a MBA in Healthcare Innovation from Reichman University in Herzliya and a BA in Philosophy and History of the Middle East in Modern Times from Tel Aviv University.